SCHEMBL18547101

SCHEMBL18547101

COC(=O)C(c1ccc(Cl)cc1)(c1ccc(Cl)cc1)c1ccc2nc(C3CC3)n(CC3CCN(C(=O)OC(C)(C)C)CC3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 3/20 0.46
▸ P2RX2 Q9UBL9 1/20 0.46
▸ CNR1 P21554 3/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ STS P08842 1/20 0.40
▸ LMNA P02545 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ PRKDC P78527 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18547002 0.90 P2RX3 (0.45) P2RX3P2RX2CNR1HSD17B10LMNA
SCHEMBL18547268 0.88 CNR1 (0.44) CNR1MEN1KMT2ANPSR1USP2
SCHEMBL18547700 0.88 CNR1 (0.40) CNR1MEN1KMT2ANPSR1USP2
SCHEMBL18562613 0.85 P2RX3 (0.40) P2RX3P2RX2CNR1NPSR1LMNA
SCHEMBL18547185 0.85 CNR2 (0.46) P2RX3P2RX2LMNASMN1; SMN2RORC
SCHEMBL18547130 0.85 KCNH2 (0.40) P2RX3P2RX2LMNASMN1; SMN2MAPT
SCHEMBL18547398 0.84 CNR1 (0.42) P2RX3P2RX2CNR1
SCHEMBL18547342 0.83 CNR1 (0.40) P2RX3CNR1MEN1KMT2ANPSR1
SCHEMBL18547548 0.83 CNR1 (0.60) P2RX3P2RX2CNR1MEN1KMT2A
SCHEMBL18576327 0.83 P2RX3 (0.38) P2RX3P2RX2LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-01-31 — — US disclosed
US-10118900-B2 Benzimidazole derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 — — US disclosed
US-20170057929-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 P2RX3 69/4885P2RX2 94/4885CNR1 1/4885
US-20170057929-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 P2RX3 70/4885P2RX2 93/4885CNR1 1/4885
US-10118900-B2 Benzimidazole derivatives useful as CB-1 inverse agonists CNR1, GPR119, CNR2 P2RX3 70/4885P2RX2 93/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback